Malaria vax trial shows positive human response

A small clinical trial of a malaria vaccine funded by the National Institute of Allergy and Infectious Diseases has delivered positive data, triggering a move to expand the research into a second trial that enlisted 400 children in Mali. The NIAID says that the 60 adults in the first trial all tolerated the vaccine very well and demonstrated a strong immune response. Mahamadou Thera at the University of Bamako, Mali led the trial, recruiting volunteers in a small town where malaria is rife--particularly during the rainy season. They each received three injections of the experimental vaccine or a rabies vaccine for the control arm of the study. The people who received the malaria vaccine experienced a six-fold growth of vaccine specific antibodies while patients getting the rabies vaccine saw their antibody levels drop with the end of the rainy season.

- here's the release
- check out the AFP report

Related Articles:
Sanaria takes new approach for malaria vaccine. Report
New malaria vaccine offers better protection. Report
Gates Foundation readies $258M for new malaria programs. Report
Genome map completed on malaria parasite. Report

Suggested Articles

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.